Tuberculosis Pipeline Review: H1 2018 - Analysis by Stage of Development, Drug Target, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

June 11, 2018

DUBLIN--(BUSINESS WIRE)--Jun 11, 2018--The “Tuberculosis - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

The pipeline guide provides a snapshot of the global therapeutic landscape of Tuberculosis (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for Tuberculosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Tuberculosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Tuberculosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Tuberculosis (Infectious Disease).

Key Topics Covered

Introduction Tuberculosis - Overview Tuberculosis - Therapeutics Development Tuberculosis - Therapeutics Assessment Tuberculosis - Companies Involved in Therapeutics Development Tuberculosis - Drug Profiles Tuberculosis - Dormant Projects Tuberculosis - Discontinued Products Tuberculosis - Product Development Milestones Appendix

Companies Mentioned

Abera Bioscience AB Akshaya Bio Inc AstraZeneca Plc Aucta Pharmaceuticals LLC BioLingus AG Bioversys AG Celgene Corp Daiichi Sankyo Co Ltd Eisai Co Ltd Eli Lilly and Co EpiVax Inc Evotec AG FIT Biotech Oy GlaxoSmithKline Plc Hager Biosciences LLC Hsiri Therapeutics LLC ImmunoBiology Ltd Innovare R & D SA De CV Inovio Pharmaceuticals Inc Johnson & Johnson LegoChem Biosciences Inc Merck & Co Inc Microbiotix Inc Novartis AG Otsuka Holdings Co Ltd Pfizer Inc QureTech Bio AB Qurient Co Ltd Sanofi Pasteur SA Sequella Inc Shionogi & Co Ltd Takeda Pharmaceutical Co Ltd Target Medicals LLC Theravectys SA TVAX Biomedical Inc

For more information about this report visit https://www.researchandmarkets.com/research/s8z37b/tuberculosis?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180611005829/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Respiratory Drugs,Infectious Diseases Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/11/2018 11:48 AM/DISC: 06/11/2018 11:48 AM


Update hourly